SCHEMBL29655133

SCHEMBL29655133

O=c1[nH]ncc2cc(OC(F)(F)F)ccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.47
PARP1 P09874 1/20 0.47
PRKCI P41743 1/20 0.47
PDE4B Q07343 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CES1 P23141 1/20 0.43
ABL1 P00519 3/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
BCR P11274 1/20 0.42
PRMT5 O14744 2/20 0.41
WDR77 Q9BQA1 2/20 0.41
KIF11 P52732 1/20 0.41
METAP2 P50579 1/20 0.41
KDM4E B2RXH2 1/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24076270 1.00 ALDH1A1 (0.47) ALDH1A1PARP1PRKCIPDE4BHSD17B10
SCHEMBL13717381 0.80 PRMT5 (0.46) ALDH1A1PARP1PRKCIPDE4BHSD17B10
SCHEMBL1009542 0.80 HSD17B10 (0.51) ALDH1A1PARP1PRKCIPDE4BHSD17B10
SCHEMBL10598655 0.78 TRPA1 (0.57) ALDH1A1TDP1ABL1METAP2KDM4E
SCHEMBL29655093 0.76 METAP2 (0.56) ALDH1A1PARP1PRKCIPDE4BHSD17B10
SCHEMBL24076262 0.76 METAP2 (0.56) ALDH1A1PARP1PRKCIPDE4BHSD17B10
SCHEMBL1536398 0.75 ROCK1 (0.52) PARP1CES1KIF11KDM4ECRHBP
SCHEMBL31243810 0.74 METAP2 (0.57) ALDH1A1ABL1HTTBCRKIF11
SCHEMBL10601519 0.74 METAP2 (0.57) ALDH1A1ABL1HTTBCRKIF11
SCHEMBL24076878 0.74 PARP1 (0.49) ALDH1A1PARP1PRKCIPDE4BHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109843874-B Phthalazine derivatives useful as inhibitors of PARP1, PARP2 and/or tubulin for the treatment of cancer 加利福尼亚大学董事会 2022-05-27 CN disclosed